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Abstract 
Purpose: To prepare pegylated ethosomal Paclitaxel® by reverse phase evaporation technique, and 
evaluate its cytotoxic effect on SK-MEL-3 cell line. 
Methods: Nanodrug was prepared by reverse phase evaporation technique. The characteristics of the 
nanoparticles were evaluated by a zetasizer and scanning electron microscopy (SEM). Drug loading 
and encapsulation efficiency as well as paclitaxel® release were determined spectrophotometerically at 
227 nm while the cytotoxicity of the pegylated ethosomal nanoencapsulated Paclitaxel® was 
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on SK-MEL-3 
cell line. 
Results: The mean diameter and zeta potential of drug-loaded pegylated ethosomal particles and blank 
pegylated ethosomes were 138.1 ± 2.7 nm and -13.1 mV, and 102.3 ± 2.1 nm and -19.2 mV, 
respectively, while drug loading and encapsulation efficiency were 2.82 ± 0.27 and 96 ± 1.27 %, 
respectively. The drug release pattern indicates that the half-life (t1/2) of the nanodrug was 
approximately twice that of the free drug for both static and dynamic release. Toxicological results 
indicate approx. 4.5-fold cytotoxicity against SK-MEL-3 cell line compared with the free drug. 
Conclusion: This study shows that pegylated ethosomal Paclitaxel® is significantly considerably more 
toxic than the free drug on SK-MEL-3 cell line, thus making it an potential alternative to the standard 
therapy. It is, however, necessary to evaluate the nanoformulation in vivo. 
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Therapeutic nanoparticles are solid colloidal 
particles ranging from 1 - 1000 nm. They are 
essentially macromolecules in that an active 
substance (drug or bioactive material) is 
entrapped, dissolved, encapsulated or attached 
to them [1]. Nanoparticles can produce controlled 
release, mask physicochemical properties, 
reduce drug toxicity and improve bioavailability, 
efficacy and biodistribution of the active 
substance [2].  
 
Paclitaxel® is a potent anticancer agent, but its 
clinical use of the drug is limited due to low 
solubility and poor gastrointestinal absorption [3].  
To increase solubility, the drug is mixed with 
Cremophor EL and alcohol under the trade 
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names, Taxol® or Paxene®. Cremophor EL is a 
solvent for biological and pharmacological 
substances but has various side effects, such as 
hypersensitivity, nephrotoxicity, neurotoxicity and 
hyperlipidemia, as well as alters the 
pharmacokinetics of Paclitaxel® [4]. Therefore, 
the use of nanotechnology-based devices as 
Paclitaxel® carriers is recommended to enhance 
therapeutic efficacy and decrease the side 
effects of the drug [5]. Based on this approach, 
an approved formulation of Paclitaxel® by Food 
and Drug Administration (FDA) under the trade 
name of Abraxane® has been prepared. 
Abraxane® - a free Cremophor EL and an 
albumin-bound Paclitaxel® nanoparticle is used 
to treat recurrent metastatic breast cancer [6].  
 
Ethosome is a type of nanoparticulate platform, 
which is actually a liposomal nanoparticle. Due to 
significant skin penetration, ethosomes have 
been extensively used for drug delivery to skin 
[7]. They have also been used in systemic drug 
delivery to treat HIV infections, shaking palsy, 
angiocardiopathy and topical delivery of various 
drugs. Enhancement of skin penetration makes 
ethosomes suitable drug carriers for skin-related 
diseases, such as skin carcinoma and psoriasis. 
Two properties facilitate nanoparticle penetration 
of skin. First, the ethanol in ethosomes increases 
lipidic membrane fluidity of skin cells. Second, 
deformability also enhances skin penetration by 
nanoparticles [8].  
 
Malignant melanoma is the most aggressive form 
of skin cancer. The outbreak of the disease is 
faster than any type of cancer worldwide. Early 
detection, chemotherapy and surgery are the 
treatment options of the disease. However, 
prognosis for metastatic melanoma is poor [9]. 
Many researchers studied Paclitaxel® as a 
chemotherapeutic agent for the treatment of 
melanoma [10,11]. In this study, the study was to 
develop and characterize Paclitaxel®-loaded 
ethosome nanoparticles and compare the 
efficacy of the nanodrug with that of the free drug 






Paclitaxel®, cholesterol, phosphatidylcholine and 
MTT (0.5 mg/mL) were purchased from Sigma 
Company (Sigma, USA). Polyethylene glycol 
3350 (PEG3350) and RPMI-1640 medium were 
obtained from Emrooz Chemical Industries 
(Kimiagaran Emrooz Chem. Ind., Iran) and 
Invitrogen (USA), respectively. Isopropanol and 
ethanol 99.4 % were purchased from Merck 
(Germany). SK-MEL-3 cell line was supplied by 
Pasteur Institute of Iran. All other materials were 
of analytical grade. De-ionized water was used 
all through the study. 
 
Preparation of nanoparticles 
 
Nanoparticles were prepared using the reverse 
phase evaporation technique in order to 
synthesize ethosome with a high level of 
encapsulation efficiency [12]. 
 
Paclitaxel®, cholesterol, PEG3350 and 
phosphatidylcholine (1:6.5:9:28 weight ratio) 
were dissolved in deionized water and ethanol 
99.4 % (67.5:32.5 volumetric ratio). Then, the 
resultant solution was stirred (100 rpm, 37 oC) to 
obtain a clear yellow suspension. Later, the 
formulation was sonicated in a bath sonicator (50 
W, Bandelin Sonopuls HD 2070, Bandelin Elec., 
Germany) for 6 min in order to reduce the size of 
ethosome [13]. A similar procedure was also 
used for preparation of a control solution without 
drug. 
 
Characterization of nanoparticles 
 
Mean diameter, size distribution and Zeta 
potential of particles were determined using 
Zetasizer (Zen 3600; Malvern Instruments Ltd, 
Malvern Worcestershire, UK) and Zetaplus 
(Brookhaven instrument corp., USA). The 
morphology of nanoparticles was studied using 
Scanning Electron Microscope (FE-SEM; Hitachi 
S-4150; Japan). 
 
Drug loading and encapsulation efficiencies 
 
In order to determine drug loading and 
encapsulation efficiencies, 2 mL of the pegylated 
form of ethosome nanoparticles that was loaded 
with Paclitaxel® was centrifuged at 14000 rpm 
and – 4 oC for 60 min (Sigma laborazentrifuge, 
Germany). The concentration of the drug in 
supernatant was determined by spectrophoto-
metrically (Shimadzu UV – 1601PC, Germany) at 
227 nm Drug encapsulation (EE) and loading 
(LE) efficiencies were calculated as in Eqs 1 and 
2, respectively. 
 
EE (%) = {(Di – Ds)/Di}100 …………………. (1) 
 
where Di is the initial drug concentration (in 
mg/ml) and Ds is the drug concentration in the 
supernatant (in mg/ml). 
 
LE (%) = Dn/Wn)100 ………………………. (2) 
where Dn is the amount of drug in the 
nanoparticles (in mg) and Wn the weight.  
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In vitro drug release studies 
 
In order to study the release pattern of 
Paclitaxel®, membrane diffusion technique was 
used. For this purpose, equal concentrations of 
pegylated ethosomal drug and standard drug 
solutions (1 mL) were poured into two separate 
dialysis bags (mol wt cut-off of 12000 Da, Sigma, 
USA). Thereafter, the dialysis bags were 
submerged in two separate graduated cylinder 
each containing 25 mL of PBS (pH = 7.4) and 
stirred (100 rpm, 37 °C). The amount of released 
drug in buffer phosphate was measured 
spectrophotometrically at various time intervals. 
At time intervals, a 2 ml sample of the release 
medium was removed and replaced with fresh 
buffer to maintain the constant volume. Then, 
cumulative drug release versus time was 
calculated. 
 
In vitro cytotoxicity studies 
 
The cytotoxicity of Paclitaxel® loaded into 
pegylated ethosomal nanoparticles was 
determined by MTT assay in SK-MEL-3 cell line 
on 96-well plates. Cells were seeded in dilution 
rate of 1 × 104 for each well in RPMI-1640 
medium containing 10 % fetal bovine serum and 
1 % penicillin/streptomycin (37 oC, 5 % CO2). 
They were allowed to attach for 48 h. Thereafter, 
culture media were removed and cells were 
treated with free Paclitaxel® and pegylated 
ethosomal Paclitaxel® at concentrations of 6.44, 
3.22, 1.61, 0.805, 0.4025, 0.20125 and 0.100625 
µM. After 24 h, the drug containing culture was 
removed and 80 µL MTT solutions (0.5 mg/mL, 
pH 7.4) was added to each well and incubated 
for 2 h. Later, MTT was discarded and 100 µL 
isopropanol 100 % was added to dissolve the 
formazan crystals. Finally, absorbance was read 
at 540 nm in an Elisa reader (BioTek 
Instruments, VT, USA). IC50 was measured by 




The results are expressed as mean ±standard 
deviation (SD, n = 3). The data were statistically 
analyzed by one-way analysis of variance 
(ANOVA) using IBM Statistics SPSS software 
version 19, and statistical significance was set at 




Characteristics of nanoparticles 
 
Size, size distribution and zeta potential of the 
nano drug and the blank nanoparticles are 
presented in Table 1. Nanoparticle morphology, 
based on SEM indicates the suitability of the 
preparation method as the micrographs showed 




Figure 1: SEM image of pegylated ethosomal 
Paclitaxel® nanoparticles prepared by reverse phase 
evaporation technique (×30,000) 
 
In vitro drug release  
 
The amount of dynamically and statically 
released Paclitaxel® from pegylated ethosomal 
formulation and standard drug after definite time 
intervals over a period of 2 days are displayed in 
Figures 2 and 3. 
 
In vitro cytotoxicity  
 
The cell viability of Paclitaxel® and Paclitaxel®-
loaded ethosome nanoparticles on SK-MEL-3 
cell line after 24 h incubation is illustrated in 
Figure 3. 
 
The   maximum   cytotoxic   effect  of   pegylated  
 
Table 1: Physicochemical properties of pegylated nanoethosomal Paclitaxel® 
  






nanoparticles with drug 138.1±2.7 -13.1 0.1 
Pegylated ethosomal 
nanoparticles without drug 102.3±2.1 -19.2 0.12 
All the data are presented as mean ±SD (n = 3) 
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ethosomal Paclitaxel® nanoparticles and the free 
drug on SK-MEL-3 cell line after 24 h of were 1.8 
± 0.1 and 8.2 ± 1.01, respectively. 
 
 
Figure 2: Release profile of free form of Paclitaxel® 




Figure 3: Release pattern of Paclitaxel® from 
pegylated ethosomal nanoparticles obtained by static 




Ethosomes are safe lipidic nanoparticles 
composed of phospholipid and high 
concentrations of water and ethanol (20 – 45 %). 
The property of skin penetration of ethosomes 
has attributed to the synergism between the 
particles, ethanol and skin lipids [14]. 
 
Nanoparticles were approximately homogenous 
that confirmed by zetasizer. Sonication caused 
the nanoparticles to become smaller and more 
uniform. However, it has been observed that the 
size of the nanoparticles was higher than that of 
the blank nanoparticles. This phenomenon has 
also been observed in a previous study [15]. 
 
In addition, the zeta potential of the 
nanoformulation was more positive than the 
blank nanoparticles, thus indicating the positive 
charge of Paclitaxel®. 
 
In both formulations, a burst release occurred in 
the first 3 h. Release rate was gradually 
decreased which may come from presence of 
PEG. However, the rate of dynamic release of 
drug was more prominent compared to static in 
which 12.4 % and 27.5 % of drug dynamically 
released, while 9.2 % and 22.4 % of drug was 
statically released from pegylated ethosomal 
Paclitaxel® and the free drug formulations, 
respectively. 
 
Otsuka et al also found that the presence of 
polyethylene glycol can lead to enhancement of 
stability, and consequently increased drug 
delivery to the tumor and hence improvement in 




Figure 4: Cell viability of Paclitaxel® and Paclitaxel®-loaded ethosome nanoparticles on SK-MEL-3 cell line, 
compared with control, after 24 h incubation 
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MTT assay is a valid test to evaluate the efficacy 
of the nanoformulation in vitro, and hence it was 
used in the present study to assess the 
cytotoxicity of Paclitaxel® on melanoma cell line 
SK-MEL-3. The nanoformulation decreased cell 
viability by 33 % compared with the free form. 
 
The results showed the IC50 of pegylated 
ethosome formulation for SK-MEL-3 cell line is 
less than that of the standard drug. Based on the 
definition of IC50 (8.2 free drug against 1.8 of 
nanoformulation), the cytotoxicity of the 
nanoformulation against SK-MEL-3 is about 4.5 




Reverse phase evaporation technique is a 
suitable method for the preparation of 
Paclitaxel® nanoparticles. The formulated 
nanodrug has a longer half-life and stronger 
cytotoxic effect than the free drug form. However, 
in vivo studies are required to ascertain the 
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